GlassScriptPhysician profile
Evan R Butlin
NPI 1396001087
$5,390.33
in general payments reported to CMS, 2019-2025
22 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,205 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,600 · Food and Beverage: $2,033 · Travel and Lodging: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,599.95 |
| Food and Beverage | $2,033.30 |
| Travel and Lodging | $757.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,274.07 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $477.41 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $336.68 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $227.30 | 2024-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $204.66 | 2024-2025 | Dupixent |
| Genzyme Corporation | $202.35 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Merck Sharp & Dohme LLC | $80.74 | 2024-2025 | Zerbaxa, Recarbrio, Prevymis |
| Viatris Specialty LLC | $63.44 | 2025 | Yupelri |
| Grifols USA, LLC | $61.52 | 2024 | Prolastin-C Liquid, Xembify |
| Ani Pharmaceuticals, INC. | $47.76 | 2025 | Purified Cortrophin Gel |
| Avadel Cns Pharmaceuticals, LLC | $44.16 | 2024-2025 | Lumryz |
| Verona Pharma, INC. | $43.39 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $39.77 | 2024-2025 | Tyvaso |
| Electromed, INC. | $35.48 | 2025 | Smartvest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30.41 | 2024 | Sunosi |
| Inspire Medical Systems, INC. | $30.31 | 2024 | Inspire |
| Mylan Specialty L.P. | $22.50 | 2024 | Yupelri |
| Philips North America LLC | $20.46 | 2025 | Vest Therapy Und |
| Vifor Pharma, INC. | $20.03 | 2025 | Zemaira |
| Novartis Pharmaceuticals Corporation | $14.20 | 2024 | |
| Jazz Pharmaceuticals INC. | $13.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Butlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.